Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, double-blind, randomized, and controlled study. The investigational
product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week
course of therapy.
DLBS1033 effectively demonstrated fibrinolytic, fibrinogenolytic as well as antithrombotic
activities. Hypercoagulation state with high fibrinogen level is usually found in diabetes
mellitus patients.
Therefore, the hypothesis of interest of this study is that DLBS1033 will reduce fibrinogen
level of diabetes mellitus patients better than that of the Control Group.